Klinika Ambroziak Sp. z o.o. — Clinical Trial Site

68 Registered trials

20 Currently recruiting

Organisation

Klinika Ambroziak Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100045213

Address

Ul. Ulica Kosiarzy 9a, 02-953, Poland

Departments

-
#45002: Klinika Ambroziak Dermatologia
#4801: NA
#5701:Dermatology
2503 : Dermatology
502: Klinika Ambroziak Dermatologia
7404:Klinika Ambroziak Dermatologia
9228:Klinika Ambroziak Dermatologia
Ambroziak Dermatologia
Dermatologia
Dermatology
Dermatology Clinic
Klinika Ambroziak
Klinika Ambroziak Dermatologia
Klinika Ambroziak Dermatologi
Klinika Ambroziak Dermatologia
Klinika Ambroziak Sp. z o.o.
N/A
N/A. Private institution
NA
Warszawa

Clinical trials at this site (68)

Search interface

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Atopic Dermatitis (AD) 5
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder… Pending

2023-508329-28-00 Atopic Dermatitis 4
A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Alopecia areata 5
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending

2025-522831-33-00 Hidradenitis Suppurativa 4
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri… Recruiting

2025-523404-74-00 Prurigo Nodularis 4 2026-05-26
A Study of JNJ-95597528 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Recruiting

2025-523464-20-00 Moderate to Severe Atopic Dermatitis 4 2026-05-20
Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting

2025-521865-29-00 moderate-to-severe hidradenitis suppurativa 4 2026-04-30
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic… Recruiting

2025-522705-37-00 HIDRADENITIS SUPPURATIVA 4 2026-04-21
A study to assess NAV-240 in adult participants with Hidradenitis Suppurativa Recruiting

2025-523557-33-00 Moderate-to-Severe Hidradenitis Suppurativa 4 2026-04-20
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Recruiting

2025-522370-36-00 Moderate to Severe Atopic Dermatitis 4 2026-02-02
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Moderate to severe atopic dermatitis 4 2025-10-28
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16